New Products In Brief
This article was originally published in The Tan Sheet
Executive Summary
Perrigo generic Nicorette approval: The Allegan, Mich.-based generics manufacturer has received FDA approval to market store-brand versions of GlaxoSmithKline's Nicorette Fresh Mint (coated nicotine polacrilex gum 2 mg and 4 mg) smoking cessation gum, the firm announces June 14. Retail sales for GSK's Fresh Mint gum were approximately $100 mil. for the past 12 months. Perrigo currently produces generic versions of GSK's uncoated NRT gum products as well as nicotine polacrilex lozenges equivalent to GSK's Commit product. "We are pleased with this important addition to our store brand nicotine replacement therapy product offerings, even though some sales may come at the expense of our uncoated gum products," Executive VP and General Manager - Perrigo Consumer Healthcare John Hendrickson states. The product will begin shipping to food, drug, mass market, dollar store and club store retailers in the fourth quarter and will cost approximately 25% to 40% less than the branded, the firm says...
You may also be interested in...
GSK Invests In Consumer Unit To Overcome Generic Threat, Low Alli Sales
GlaxoSmithKline expects to overcome increasing generic competition by growing its consumer health business and investing in emerging markets, rather than by pursuing a mega-merger like Pfizer-Wyeth
GSK Invests In Consumer Unit To Overcome Generic Threat, Low Alli Sales
GlaxoSmithKline expects to overcome increasing generic competition by growing its consumer health business and investing in emerging markets, rather than by pursuing a mega-merger like Pfizer-Wyeth
GSK Invests In Consumer Unit To Overcome Generic Threat, Low Alli Sales
GlaxoSmithKline expects to overcome increasing generic competition by growing its consumer health business and investing in emerging markets, rather than by pursuing a mega-merger like Pfizer-Wyeth